Merck & Co., Inc. logo

Merck & Co., Inc.

TickerMRKVenueUSSectorHealthcarePrimary listingBeta0.23
$143.7-1.56%
FinScore53

Merck & Co., Inc. is a United States-based company in the Healthcare sector with a market capitalisation of $360.1B. Its FinScore is 53/100; its highest-scoring layer is Quality (79) and its lowest is Value (23). The shares trade at 113.5x trailing earnings and are up 37% year to date.

Market cap
$360.1B
P/E (TTM)
113.5x
Dividend yield (TTM)
2.33%
ROE
6.6%

Share price performance

Loading chart…

About Merck & Co., Inc.

www.merck.com

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Profile
Sector
Healthcare
Industry
Drug Manufacturers - General
HQ
United States
Fiscal year-end
December
Trading currency
USD
Reporting currency
USD
Fundamentals updated
24 days ago
Market
Market cap
$360.1B
Shares outstanding
2.5B
P/E (TTM)
113.5x
Dividend yield (TTM)
2.33%
Beta (issuer)
0.22
Revenue (latest FY)
$64.9B

Revenue breakdown

FY 2025$65.0B
  • Pharmaceutical segment
    89.4%$58.1B
  • Animal Health segment
    9.8%$6.4B
  • Other Segments
    0.8%$515.0M

FinScore

As of 2026-10-19
Overall53
Quality79
Growth40
Value23
Momentum79
Relative Strength28

Snapshot

Ownership

As of 2026-06-30
Institutional
82.0%
Insider
0.0%
Free float
99.9%
Top-5 institutional holders
26.8%
Shares outstanding
2.5B
Sign up to see the top holders

Sign up or log in to see Analysis

Analysis for Merck & Co., Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Financials

Financials for Merck & Co., Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Estimates

Estimates for Merck & Co., Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Peers

Peers for Merck & Co., Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Valuation

Valuation for Merck & Co., Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see News

News for Merck & Co., Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.